Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Puma Neratinib Research Grant Opportunity: submit by Monday, April 19, 2021
Study Proposal Submission-NCCN iEnvision
NCCN AstraZeneca NSCLC Research Opportunity: submit LOIs by Monday, May 3, 2021
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

NCCN ORP Drug Pipeline Review Research Services

The NCCN ORP establishes Scientific Advisory Boards (SABs) to provide advice and direction to industry collaborators developing new and innovative oncology drugs and biologics. SABs are made up of notable academic scientific, clinical, and pharmacy experts in oncology. Each SAB is unique with leading experts specifically matched to the drug development plans and strategies of the company. The principal mission of each SAB includes:

  • reviewing the quality and relevance of the scientific and technical information being used or proposed as the basis for drug development
  • assisting in advancing the development of preclinical and clinical-stage product candidates
  • reviewing research programs and advising Industry on specific clinical and scientific matters related to oncology drug development
  • assisting in developing an academic and industry approach to drug development